VTX-958
- Generic Name
- VTX-958
Ventyx's VTX958 Shows Promising Endoscopic Response in Phase 2 Crohn's Disease Trial Despite Missing Primary Endpoint
• Phase 2 trial of VTX958, an oral TYK2 inhibitor, demonstrated significant endoscopic improvement in Crohn's disease patients, with up to 32.4% achieving endoscopic response at Week 12.
• While the trial missed its primary CDAI endpoint due to high placebo response, VTX958 showed robust dose-dependent improvements in objective measures including endoscopic scores and inflammatory biomarkers.
• The drug maintained a favorable safety profile, supporting its potential as a novel oral therapy option for Crohn's disease patients, with ongoing analysis of 52-week extension data to inform future development.
Ventyx Biosciences Advances NLRP3 Inhibitor Portfolio with Phase 2 Trials
• Ventyx Biosciences initiated a Phase 2 trial of VTX3232 for obesity and cardiometabolic risk factors, with topline data expected in the second half of 2025.
• A Phase 2 trial of VTX2735 for recurrent pericarditis is expected to begin in January, with topline results anticipated in the second half of 2025.
• Topline data from an ongoing Phase 2 biomarker trial of VTX3232 in early Parkinson’s disease are expected in the first half of 2025.
VYNE Therapeutics Advances VYN201 and VYN202 in Vitiligo and Psoriasis Trials
• VYNE Therapeutics completes enrollment for Phase 2b trial of VYN201 gel (repibresib) in nonsegmental vitiligo, with top-line data expected mid-2025.
• A Phase 1b trial of oral VYN202 for moderate-to-severe plaque psoriasis has begun, with results anticipated by the end of 2025.
• Both VYN201 and VYN202 are BET inhibitors designed to address immune-mediated conditions with high unmet needs.
Ventyx Biosciences and Tonix Pharmaceuticals Report Pipeline Updates and Financial Results
• Ventyx Biosciences advances VTX3232 into Phase 2 trials for early Parkinson's and obesity, expecting topline results in H1 and H2 2025, respectively.
• Tonix Pharmaceuticals submitted an NDA for TNX-102 SL for fibromyalgia, with a potential FDA decision expected in December 2024.
• Tonix Pharmaceuticals secured a DoD contract worth up to $34 million for antiviral drug development and reported Q3 2024 product revenue of $2.8 million.
• Ventyx Biosciences reported a cash balance of $274.8 million, expected to fund operations into at least H2 2026, while Tonix Pharmaceuticals reported $28.2 million in cash.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath